Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Kelly

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Molecules (Basel, Switzerland)|October 12, 2018
<sup>66</sup>Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?Alejandro Amor-Coarasa, James M Kelly, Shashikanth Ponnala, et al.
Nuclear Medicine and Biology|August 14, 2017
Continuation of comprehensive quality control of the itG <sup>68</sup>Ge/<sup>68</sup>Ga generator and production of <sup>68</sup>Ga-DOTATOC and <sup>68</sup>Ga-PSMA-HBED-CC for clinical research studiesAlejandro Amor-Coarasa, James M Kelly, Monika Gruca, et al.
Nuclear Medicine and Biology|October 23, 2017
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of <sup>68</sup>Ga<sup>3+</sup>, <sup>111</sup>In<sup>3+</sup>, <sup>177</sup>Lu<sup>3+</sup> and <sup>225</sup>Ac<sup>3</sup>James M Kelly, Alejandro Amor-Coarasa, Anastasia Nikolopoulou, et al.
EJNMMI Radiopharmacy and Chemistry|December 20, 2021
A suitable time point for quantifying the radiochemical purity of <sup>225</sup>Ac-labeled radiopharmaceuticalsJames M Kelly, Alejandro Amor-Coarasa, Elizabeth Sweeney, et al.
Molecular Imaging and Biology|March 15, 2021
A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα)James M Kelly, Thomas M Jeitner, Shashikanth Ponnala, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2018
Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic WindowJames M Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and BrachytherapyRuth Christine Winter, Mariam Amghar, Anja S Wacker, et al.
Geroscience|May 22, 2023
Cystine rather than cysteine is the preferred substrate for β-elimination by cystathionine γ-lyase: implications for dietary methionine restrictionThomas M Jeitner, Juan A Azcona, Gene P Ables, et al.
JCI Insight|October 23, 2025
FAP PET identifies earlycardiac molecular changesinduced by doxorubicin chemotherapyChul-Hee Lee, Onorina L Manzo, Luisa Rubinelli, et al.
Npj Imaging|April 16, 2026
[3-<sup>11</sup>C]Pyruvate PET detects alterations in cardiac pyruvate metabolism induced by doxorubicin chemotherapyChul-Hee Lee, Thomas Ruan, Shuvra Debnath, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Molecules (Basel, Switzerland)|October 12, 2018
<sup>66</sup>Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?Alejandro Amor-Coarasa, James M Kelly, Shashikanth Ponnala, et al.
Nuclear Medicine and Biology|August 14, 2017
Continuation of comprehensive quality control of the itG <sup>68</sup>Ge/<sup>68</sup>Ga generator and production of <sup>68</sup>Ga-DOTATOC and <sup>68</sup>Ga-PSMA-HBED-CC for clinical research studiesAlejandro Amor-Coarasa, James M Kelly, Monika Gruca, et al.
Nuclear Medicine and Biology|October 23, 2017
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of <sup>68</sup>Ga<sup>3+</sup>, <sup>111</sup>In<sup>3+</sup>, <sup>177</sup>Lu<sup>3+</sup> and <sup>225</sup>Ac<sup>3</sup>James M Kelly, Alejandro Amor-Coarasa, Anastasia Nikolopoulou, et al.
EJNMMI Radiopharmacy and Chemistry|December 20, 2021
A suitable time point for quantifying the radiochemical purity of <sup>225</sup>Ac-labeled radiopharmaceuticalsJames M Kelly, Alejandro Amor-Coarasa, Elizabeth Sweeney, et al.
Molecular Imaging and Biology|March 15, 2021
A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα)James M Kelly, Thomas M Jeitner, Shashikanth Ponnala, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2018
Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic WindowJames M Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and BrachytherapyRuth Christine Winter, Mariam Amghar, Anja S Wacker, et al.
Geroscience|May 22, 2023
Cystine rather than cysteine is the preferred substrate for β-elimination by cystathionine γ-lyase: implications for dietary methionine restrictionThomas M Jeitner, Juan A Azcona, Gene P Ables, et al.
JCI Insight|October 23, 2025
FAP PET identifies earlycardiac molecular changesinduced by doxorubicin chemotherapyChul-Hee Lee, Onorina L Manzo, Luisa Rubinelli, et al.
Npj Imaging|April 16, 2026
[3-<sup>11</sup>C]Pyruvate PET detects alterations in cardiac pyruvate metabolism induced by doxorubicin chemotherapyChul-Hee Lee, Thomas Ruan, Shuvra Debnath, et al.
Pageof 3